Skip to main content

Argenica Therapeutics Health Care

$0.375 0.005 (1.35%)

High

$0.38

Low

$0.38

Trades

2

Turnover

$1,293

Volume

3,448
30 June 2023 at 10:43am
Register to track AGN and receive email alerts.
AGN Announcements on Price Chart

Latest Announcements

Headline Date
ARG-007 Protects Brain Cells in Moderate TBI Model 22 June 2023 at 8:40am
Becoming a substantial holder 20 June 2023 at 8:45am
Becoming a substantial holder 13 June 2023 at 6:00pm
Application for quotation of securities - AGN 13 June 2023 at 10:00am
Notification regarding unquoted securities - AGN 9 June 2023 at 11:05am
Cleansing Notice 9 June 2023 at 10:50am
Application for quotation of securities - AGN 9 June 2023 at 10:40am
Release of Restricted Securities From Escrow 5 June 2023 at 5:00pm
Proposed issue of securities - AGN 2 June 2023 at 9:50am
Argenica Successfully Completes $4.0m Placement 2 June 2023 at 9:50am
Trading Halt 31 May 2023 at 9:50am
Final Phase1 Clinical Trial Report 15 May 2023 at 8:45am
Quarterly Activities/Appendix 4C Cash Flow Report 27 April 2023 at 8:25am
Latest Preclinical HIE Study Results 20 April 2023 at 8:35am
Significant Non-Dilutive Funding For Preclinical HIE Studies 30 March 2023 at 9:55am
Interim Phase 1 Safety Report Confirms Safety of ARG-007 6 March 2023 at 8:40am
Half Yearly Report and Accounts 28 February 2023 at 8:15am
Non-Dilutive Funding Received to Progress Alzheimers Studies 22 February 2023 at 8:35am
Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers 9 February 2023 at 8:40am
Investor Presentation 2 February 2023 at 8:40am
Quarterly Activities/Appendix 4C Cash Flow Report 31 January 2023 at 8:10am
Argenica Awarded $1.2m CRC-P Grant for TBI Project 20 January 2023 at 9:45am
Successful Completion of Phase 1 Clinical Trial Dosing 21 December 2022 at 8:45am
Ceasing to be a substantial holder 12 December 2022 at 6:30pm
SRC Approves Commencement Of Fourth And Final Cohort Dosing 8 December 2022 at 10:05am
Change of Director's Interest Notice 30 November 2022 at 8:40am
Notification regarding unquoted securities - AGN 30 November 2022 at 8:40am
Phase 1 Clinical Trial Progress Update 25 November 2022 at 8:45am
AGM Presentation 25 November 2022 at 8:45am
Results of Annual General Meeting 25 November 2022 at 8:45am
Safety Review Committee Approves Third Cohort Commencement 18 November 2022 at 9:25am
Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial 7 November 2022 at 8:45am
Safety Review Committee Approves Second Cohort 2 November 2022 at 9:30am
Quarterly Activities/Appendix 4C Cash Flow Report 31 October 2022 at 5:10pm
No Serious Safety Issues Observed in First Cohort 26 October 2022 at 8:35am
Notice of Annual General Meeting/Proxy Form 21 October 2022 at 8:40am
Investor Presentation 20 October 2022 at 8:30am
First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007 17 October 2022 at 9:55am
Argenica Receives $1.38m R&D Tax Incentive Cash Refund 4 October 2022 at 8:25am
Further Positive Preclinical Results for ARG-007 In HIE 29 September 2022 at 9:35am
Date of AGM and Closing Date for Director Nominations 16 September 2022 at 8:45am
Phase 1 Clinical Trial Summary 8 September 2022 at 8:59am
Argenica Receives Ethics Approval To Commence Phase 1 Trial 7 September 2022 at 8:40am
Appendix 4G & Corporate Governance Statement 23 August 2022 at 6:50pm
Appendix 4E & Annual Report 30 June 2022 23 August 2022 at 6:45pm
Ethics Application Submitted for Phase 1 Trial 11 August 2022 at 9:40am
Quarterly Activities/Appendix 4C Cash Flow Report 29 July 2022 at 8:25am
Clinical Advisory Committee Appointment 11 July 2022 at 8:45am
Notification regarding unquoted securities - AGN 11 July 2022 at 8:45am
Peer Reviewed Paper Published on Preclinical Safety Study 7 July 2022 at 8:45am
Register to track AGN and receive email alerts.